Evidence map›Paper›PMID 27562566›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2017

Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.

P D'Eufemia, R Finocchiaro, A Zambrano, V Lodato, L Celli, S Finocchiaro, P Persiani, A Turchetti, M Celli

Erratum issuedOpen access · greenAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Vitamin D and Osteogenesis Imperfecta in Pediatrics.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  3. Article
  4. Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

P D'EufemiaDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy. patdeufemia@inwind.it.
R FinocchiaroDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
A ZambranoDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
V LodatoDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
L CelliDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
S FinocchiaroDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
P PersianiDepartment of Anatomic Histologic Forensic and Locomotor Apparatus Sciences, "Sapienza" University of Rome, Rome, Italy.
A TurchettiDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
M CelliDepartment of Pediatrics, "Sapienza", University of Rome, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates serum creatine kinase isoenzyme activity in children with osteogenesis imperfecta to determine its usefulness as a biochemical marker during treatment with bisphosphonate. The changes of creatine kinase (CK) isoenzyme activity during and after discontinuation therapy were observed. These results could be useful in addressing over-treatment risk prevention.

introductionThe brain isoenzyme of creatine kinase (CKbb) is highly expressed in mature osteoclasts during osteoclastogenesis, thus plays an important role in bone resorption. We previously identified high serum CKbb levels in 18 children with osteogenesis imperfect (OI) type 1 treated for 1 year with bisphosphonate (neridronate). In the present study, serum CK isoenzymes were evaluated in the same children with continuous versus discontinued neridronate treatment over a further 2-year follow-up period.

methodsThis study included 18 children with OI type 1, 12 with continued (group A) and 6 with ceased (group B) neridronate treatment. Auxological data, serum biochemical markers of bone metabolism, bone mineral density z-score, and serum total CK and isoenzyme activities were determined in both groups.

resultsSerum CKbb was progressively and significantly increased in group A (p < 0.004) but rapidly decreased to undetectable levels in group B. In both groups, the cardiac muscle creatine kinase isoenzyme (CKmb) showed a marked decrease, while serum C-terminal telopeptide (CTx) levels were almost unchanged.

conclusionsThis study provides evidence of the cumulative effect of neridronate administration in increasing serum CKbb levels and the reversible effect after its discontinuation. This approach could be employed for verifying the usefulness of serum CKbb as a biochemical marker in patients receiving prolonged bisphosphonate treatment. Moreover, the decreased serum CKmb levels suggest a systemic effect of these drugs.

Indexed as

BiomarkersBone Density Conservation AgentsChildChild, PreschoolClinical Enzyme TestsCreatine KinaseDiphosphonatesDrug MonitoringFemaleFollow-Up StudiesHumansIsoenzymesMaleOsteogenesis Imperfecta6-amino-1-hydroxyhexane-1,1-diphosphonateBiomarkersBone Density Conservation AgentsCreatine KinaseDiphosphonatesIsoenzymesBisphosphonatesBone metabolismCreatine kinase isoenzymesOsteoclastOsteogenesis imperfecta

Identifiers

PMID27562566
OpenAlexW2511819154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.